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Chronic pain represents one of the most impor-
tant problems. This is a common unpleasant sensory
and emotional experience associated with actual or
potential tissue damage. For instance, it has been
estimated that 10-13% of the general population in
Europe, are being disabled by persistent pain.
Conventionally, analgesic treatment is accom-
plished by three principal drug groups: nonsteroidal
anti-inflammatory drugs (NSAIDs), opioids, and
local anesthetics, administered through different
routes and modalities (1). Pain relief can be
achieved and adverse effects minimized by a combi-
nation of analgesics (2). Analgesics are comple-
mented with co-analgesic (adjuvant) drugs, special-
ly in pain of inflammatory and neuropathic type (1,
3, 4). In the case of neuropathic pain, treatment with
opioids may be of limited efficacy and combination
with co-analgesics is necessary (4ñ8). 
Co-analgesic drugs are defined as drugs that
have a primary indications other than pain but are
analgesic in some painful conditions or are capable
of decreasing the side effects of analgesic drugs (4).
Co-analgesics can also be defined as drugs that have
weak or non-existent analgesic action when admin-
istered alone, but can enhance analgesic actions
when co-administered with known analgesic agents
(4). Such combinations increase analgesia without
increasing the dose of analgesics, and therefore, can
reduce the incidence of adverse effects (4). The
combined treatment with the two types of drugs at
doses much lower than therapeutic doses may be of
great value in pain therapy (9).
Co-analgesic drugs include antidepressants,
antipsychotics, anticonvulsants, antiarrhythmics,
corticosteroids and others (4, 8, 10). Efficacy of
these drugs depends on the type of pain, its patho-
physiology, clinical status and adequacy of pain
intervention. There has been an increase in the num-
ber of these drugs and they now play an important
role in the management of chronic pain (10). 
In chronic pain, antidepressants are an essential
part of the therapeutic strategy in addition to classi-
cal analgesics (3, 8, 10). These drugs belong to the
groups of tetracyclic antidepressants (TeCAs)
(amoxapine, maprotiline), tricyclic antidepressants
(TCAs) (amitriptyline, doxepin, imipramine), selec-
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tive serotonin reuptake inhibitors (SSRIs), serotonin
and noradrenaline reuptake inhibitors (SNRIs)
(duloxetine, venlafaxine, milnacipran), and atypical
antidepressants (bupropion, trazodone, mirtazapine,
nefazodone), (3, 8). Antidepressants effective in
chronic pain act via different mechanisms as can be
seen in Table 1, (3, 10). However, other mechanisms
have also been suggested..
Antidepressants are commonly used to treat the
following chronic pain conditions: arthritis, central
pain syndrome, fibromyalgia, low back pain,
migraines, nerve damage from diabetes (diabetic neu-
ropathy) (8, 11). Their effectiveness is best document-
ed for painful diabetic neuropathy. On the other hand,
some clinical data suggest that headache can occur
after prolonged use of amitriptyline in patients with
depression but without pain symptoms (3). The expla-
nation of this phenomenon requires further research.
The analgesic potency of antidepressant drugs
has been suggested to result from the inhibition of
monoamine reuptake in the central nervous system,
which consequentially leads to an increased activity
of the antinociceptive descending pathways (3). The
antidepressants have an analgesic effect that may be,
at least partly, independent of their effect on depres-
sion (3). The dose necessary to achieve optimal
analgesia is usually lower than that required for anti-
depressant therapy, which may suggest separation of
analgesic and antidepressant effect (3).
The present study is, therefore, intended to
investigate the analgesic potential of 7-(3-chlo-
rophenyl)piperazinylalkyl derivatives of 8-alkoxy-
purine-2,6-dione, used alone or in combination with
ketoprofen in two models of induced pain in mice,
representing different types of pain stimuli. Our pre-
vious study demonstrated a potent antidepressant-
like activity of several derivatives of 8-alkoxy-
purine-2,6-dione in the forced swimming test in
mice and showed their strong affinity for the 5-HT2
and 5-HT1A receptors (12).
EXPERIMENTAL
Chemistry
The structures of the investigated compounds
1ñ4 are presented in Table 2. Compounds 1ñ4 were
synthesized by nucleophilic substitution of previ-
ously obtained 7-chloroalkyl-8-alkoxy-1,3-dimeth-
yl-3,7-dihydropurine-2,6-diones with the appropri-
ate phenylpiperazines in the presence of K2CO3. The
synthesis and physicochemical data of compounds
1ñ4 were described elsewhere (13). The investigat-
ed compounds were pharmacologically tested as
hydrochloride salts.
Table 1. The mechanism of action of antidepressants effective for chronic pain (3, 11).
Group Drugs Mechanisms 
Amitriptyline
TCA Doxepin 5-HT > NE reuptake
Imipramine inhibition  
TeCA Amoxapine NE and 5-HT reuptake
inhibition
Citalopram
Fluoxetine 5-HT > NE reuptake
SSRI Paroxetine inhibition 
Sertraline
Fluvoxamine 
Duloxetine
SNRI Venlafaxine 5-HT NE > DA reuptake
Milnacipran inhibition
Bupropion DA NE reuptake inhibition
5-HT2 receptor blockade
Trazodone 5-HT reuptake inhibition
Atypical a2-NE and 5-HT2 presynaptic
antidepressant Mirtazapine agonist; 5-HT2/3 receptor
blockade  
Nefazodone 5-HT2 receptor blockade
5-HT reuptake inhibition  
TCA - tricyclic antidepressants, TeCA - tetracyclic antidepressants, SSRI - selective serotonin reuptake
inhibitors, SNRI - serotonin and noradrenaline reuptake inhibitors; NE - noradrenaline, DA - dopamine, HT -
hydroxytryptamine.
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Animals
The experiments were carried out on male albi-
no-Swiss mice (body weight 20-26 g). The animals
were housed in constant temperature facilities
exposed to 12 : 12 h light-dark cycle and maintained
on a standard pellet diet, tap water was ad libitum.
Control and experimental groups consisted of six to
eight animals each. The investigated compounds
were administered intraperitoneally (i.p.) as a sus-
pension in 0.9% NaCl.
Statistical analysis
The statistical significance was calculated
using Studentís t-test. Differences were considered
statistically significant at p ≤ 0.05.
Methods
The writhing syndrome test
Mice were treated with 0.25 mL of 0.02%
phenylbenzoquinone solution 30 min after i.p.
administration of the investigated compound or the
vehicle. Then, the mice were placed individually in
glass beakers and 5 min were allowed to elapse.
After that period, each animal was observed for 10
min and the number of characteristic writhes was
counted. The control group was given i.p. 0.9%
NaCl. The analgesic effect of the tested substances
was determined by a decrease in the number of
writhes observed (14). The ED50 values and their
confidence limits were estimated by the method of
Litchfield and Wilcoxon (15). 
The hot plate test
In the hot plate test, mice were treated i.p.
either with the test compound or the vehicle 30 min
before placing the animal on a hot plate apparatus
(Hot Plate 2A Type Omega) with the temperature
controlled at 55-56OC. The time elapsing until the
animal licks its hind paws or jumps is recorded
using a stop-watch (16). The ED50 values and their
Table 2. Structure and binding affinity data for serotonin 5-HT1A and 5-HT2 receptors of the investigated compounds.
Ki (nM) ± SEM    
Compound R n R1
5-HT1A 5-HT2
1 C3H7 2 m-Cl 15 ± 1a 28 ± 2a 2 C2H5
2 C3H5 2 m-Cl 12 ± 2a 15 ± 1a
3 C2H5 1 m-Cl 190 ± 28a 23 ± 2a
4 C3H7 1 m-Cl 288 ± 18a 25 ± 2a
a Data taken from ref. (12).
Table 3. The influence of the investigated compounds and ketoprofen on the pain reaction in the ìwrithing
syndromeî test in mice.
Compound
Dose Mean number of 
mg/kg writhings ± SEM  
Control 30.5 ± 0.7  
1 5 8.7 ± 0.8** 
2 5 9.3 ± 0.2** 
3 5 4.7 ± 0.6*** 
4 5 3.9 ± 0.4*** 
Ketoprofen 5 1.9 ± 0.1***
Data are presented as the means ± SEM of 6-8 mice per group. The results were analyzed by Studentís t-test.
** p < 0.01,*** p < 0.001 vs. control.
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confidence limits were estimated by the method of
Litchfield and Wilcoxon (15). 
RESULTS 
Analgesic activity in the writhing syndrome test
All xanthine derivatives were tested in the
writhing test. In this test, pain was induced by injec-
tion of an irritant (such as phenylbenzoquinone) into
the peritoneal cavity of mice. In this test, the inves-
tigated compounds (1ñ4) administered at a dose 5
mg/kg, showed significant analgesic properties
(Table 3). Ketoprofen was a drug of reference in this
assay. The mean number of writhing responses in
the vehicle-treated mice was 30.5. The strongest
analgesic effect was observed for compounds 3 and
4. Compound 3 injected i.p. at a dose 5 mg/kg body
weight, reduced the number of writhes in response
to an irritating stimulus by 84.6%. Administration of
compound 4 at a same dose, produced a strong anal-
gesic effect (inhibition by 87.2%). Compound 1
reduced the number of abdominal writhings by
71.4% with respect to the control group, while com-
pound 2 statistically significantly diminished the
number of abdominal constrictions by 69.5%, as
compared to the 0.9% NaCl-pretreated animals.
In this model of pain, each drug was used alone
to test its analgesic effect, and in combination with
ketoprofen (at the dose 5 mg/kg) to look for a possi-
ble potentiation of its analgesic effect.
The combination of the investigated compound
3 and ketoprofen produced a slightly higher effect in
the writhing test, compared to each of them used
alone (reduction of the number of writhes by
96.8%), (Table 4). The combination of the investi-
gated compound 4 and ketoprofen also produced a
slightly higher effect in the writhing test, compared
to each of them used alone (reduction by 97.6%). As
regards compound 2 and ketoprofen, this combina-
tion also increased the analgesic activity in the
writhing test (95.5% increase versus 69.5 and
93.7%, respectively), (Table 4). Compound 1 and
ketoprofen reduced the number of writhes in
response to an irritating stimulus by 95.2%. This
combination produced higher effect in the writhing
test, compared to compound 1 (71.4%) and ketopro-
fen (93.7) used alone.
Hot plate test
As demonstrated in Table 5, in the hot plate
test the investigated compounds 1-4 did not exerted
an analgesic activity at the dose of 5 mg/kg body
weight. Morphine, which was a drug of reference in
this assay, showed a high antinociceptive potency.
DISCUSSION AND CONCLUSION
Serotonin (5-hydroxytryptamine, 5-HT), like
noradrenaline, is believed to be one of important
modulators of painful stimulus transmission while
spinal serotonergic receptors play an important role
in the inhibition of nociceptive reaction connected
with the release of stimulatory amino acids and sub-
stance P (17). Many types and subtypes of 5-HT
receptors were identified in the CNS, however, only
four of them - 5HT1-4 were found in the spinal cord
(17). When administered intrathecally, 5-HT had an
antinociceptive effect in acute pain models. In the
periphery, 5-HT was shown to produce analgesic
response in pain accompanying inflammatory
process.
Animal studies demonstrated antinociceptive
action of serotonin via spinal 5-HT receptors in the
writhing test. Analgesic action of different sub-
stances in that test could result from their effect on
the serotonergic system (18) probably mediated by
5-HT2 and 5-HT3 receptors. It was abolished by
antagonists of these receptors (ketanserin, cyprohep-
Table 4. The influence of the combination of the investigated compounds and ketoprofen on pain reaction in
the ìwrithing syndromeî test in mice.
Compound
Dose Mean number of 
mg/kg writhings ± SEM  
Control  31.5 ± 2.6***
1 + Ketoprofen 5 1.5 ± 0.8*** 
2 + Ketoprofen 5 1,4 ± 0.2*** 
3 + Ketoprofen 5 1.0 ± 0.1***
4 + Ketoprofen 5 0.8 ± 0.1***
Data are presented as the means ± SEM of 6ñ8 mice per group. The results were analyzed by Studentís t-test.
*** p < 0.001 vs. control.
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tadine, ondansetron). The 5HT1 receptors seemed to
play a less important role in this model of pain and
their antagonists did not abolish nociceptive action
of agonists. The role of 5HT1A receptors in thermal
pain models is unclear (17). It appears that 5HT1A
receptors do not play a role in the hot plate test and
antinociceptive action in this test can result from the
stimulation of serotonin type 3 and probably 2
receptors.
Summarizing, the problem of implication of
specific serotonin receptor subtypes in different ani-
mal models of pain is very complex and deserves
further clarification (19, 20). It should be remem-
bered that the role of serotonin in the CNS and its
receptor-mediated actions, including analgesic
effect, are closely connected with other neurotrans-
mitter systems (19, 20). 
Animal studies revealed analgesic potential of
antidepressant drugs which is partly mediated by
serotonin receptors but can also stem from complex
interactions between serotonergic, adrenergic and
opioid systems (21). Due to their antinociceptive
actions, some antidepressant drugs can be used as
co-analgesics (3, 10, 11). Trazodone which present-
ed a weak activity of a serotonin reuptake inhibitor
and 5-HT2A receptor antagonist, also showed anal-
gesic activity in animal studies (22) but the clinical
trials did not confirm its beneficial effects in chron-
ic pain (3).
In our previous studies, all investigated com-
pounds were demonstrated to be highly active 5-
HT2A receptor ligands. Compounds 3 and 4 showed
8.3- and 11.5-fold stronger affinity for 5-HT2 recep-
tor than for 5-HT1A whereas compounds 1 and 2
were found to be highly active 5-HT1A receptor lig-
ands. On the other hand, several derivatives of 8-
alkoxypurine-2,6-dione revealed a potent antide-
pressant-like activity in the forced swimming test in
mice (12). In our study, the most potent effect in the
forced swimming test was produced by compounds
3 and 4 (12). The investigated compounds exhibited
a similar mechanism of action as trazodone (23).
Perhaps it was because of the combination of the
weak activity of a serotonin reuptake inhibitor and a
5-HT2A receptor antagonist.
Pain is often associated with inflammatory
conditions. Non-steroidal anti-inflammatory drugs
(NSAIDs) are the most commonly used analgesic
agents. NSAIDs are clinically effective because they
alleviate pain and inflammation (24-26) Thus, the
NSAID (ketoprofen) was selected in the present
study as a standard drug to be co-administered with
the tested compounds (1ñ4), 7-(3-chlorophen-
yl)piperazinylalkyl derivatives of 8-alkoxypurine-
2,6-dione.
The aim of the first stage of our studies was to
determine analgesic activity of the test compounds
and ketoprofen in the writhing test and the hot plate
test.
7-(3-Chlorophenyl)piperazinylalkyl deriva-
tives of 8-alkoxypurine-2,6-dione were adminis-
tered at a dose of 5 mg/kg, because, as previous
studies have shown, it was the lowest used dose that
did not reduce the motility of animals (12). Higher
doses of 10-30 mg/kg significantly decreased mobil-
ity. Therefore, this dose was used in order to exclude
false-positive results in the tests assessing analgesic
activity. 
The analgesic activities of the 7-(3-
chlorophenyl)piperazinylalkyl derivatives of 8-
alkoxypurine-2,6-dione 1ñ4 were measured using
the phenylbenzoquinone-induced writhing syn-
Table 5. The influence of the investigated compounds and ketoprofen on the pain reaction in the hot plate test
in mice.
Compound
Dose Time of reaction to  
mg/kg ain stimulus (s) ± SEM 
Control  30.0 ± 2.4
1 5 27.2 ± 1.3
2 5 29.2 ± 3.0
3 5 31.6 ± 2.2
4 5 28.3 ± 1.6
Morphine 5 50.2 ± 0.7 **
Ketoprofen 5 19.2 ± 3.1  
Data are presented as the means ± SEM of 6ñ8 mice per group. The results were analyzed by Studentís t-test.
** p < 0.01 vs. control.
584 MA£GORZATA ZYGMUNT et al.
drome test. This test consists in intraperitoneal
injection of the chemical irritant followed by subse-
quent counting of ìwrithesî, i.e., characteristic con-
tractions of abdominal muscles accompanied by a
hind limb extensor motion. This test detects periph-
eral analgesic activity; however, some psychoactive
agents (including clonidine and haloperidol) also
show activity in this test. Compounds with anti-
inflammatory properties, such as NSAIDs show a
significant activity in this assay, viz. they abolish the
reflex stimulated by the administration of an irritat-
ing substance, like phenylbenzoquinone
All tested compounds 1ñ4 demonstrated a sta-
tistically significant analgesic activity in this test
with compounds 3 and 4 revealing the highest
(similar to ketoprofen) potency. However, the
observed effect was not stronger than that of keto-
profen alone at the same dose. It is probable that
analgesic activity of the test compounds is mediat-
ed by 5-HT2 receptors because they bound several
times more strongly to 5-HT2 than to 5-HT1A recep-
tors. It was additionally confirmed by the fact that
analgesic activity of different substances in the
writhing test could result from the stimulation of 5-
HT2 receptors while 5-HT2 played a less important
role (18, 27). 
Peripheral 5-HT2 and presynaptic 5-HT1A
receptors have been clearly shown to be involved in
5-HT-induced hyperalgesia (27). On the other hand,
it is not excluded that 5-HT1A receptors also played
a role in this effect. In order to clarify the mecha-
nism of action, we planned to determine analgesic
activity of the test compounds, given together with
antagonists of serotonin receptors. In addition, the
involvement of serotonin receptors in the analgesic
effect was supported by the fact that 5-HT when
applied peripherally, was a potent proinflammatory
and noxious agent, which caused hyperalgesia both
in humans and rodents (27). 5-HT, released from
platelets, mast cells, and basophils in injured or
inflamed tissues, may play a role in inflammatory
chemical milieu. Hyperalgesia, which is the major
symptom of inflammation and tissue injury, proba-
bly caused by the phenylbenzoquinone, was the
result of sensitization of nociceptors by a variety of
inflammatory mediators. 5-HT is one of these medi-
ators; indeed it has been shown be able to sensitize
peripheral nerve fibers to other inflammatory medi-
ators, such as bradykinin (27).
Next, we determined analgesic activity of the
test compounds in another model of pain, namely
the hot plate test. None of the tested xanthine deriv-
atives prolonged the reaction time to a thermal stim-
ulus. The proven activity in the writhing test with
the concomitant lack of activity in the hot plate test
indicates rather peripheral than central mechanism
of analgesic action of the test compounds. 
The next stage of research aimed to determine
whether the test compounds, shown previously to
possess antidepressant activity (12), can be used as
co-analgetics. To answer this question, the com-
pounds were tested for analgesic activity in the
writhing test when administered in combination
with ketoprofen. 
The compounds slightly enhanced the anal-
gesic effect of ketoprofen in the writhing test when
given together. 
In summary, compounds 1-4 were found to
have analgesic effect when given alone, however,
their effects differed in dependence on the pain
model used. The analgesic activities were observed
only in the writhing test. The strongest effect (simi-
lar to ketoprofen) was shown by compounds 3 and
4. The possible mechanism of the antinociceptive
effect of these compounds is thought to involve the
activation of an analgesia mediated by serotonergic
pathways or a combination of this mechanism with
other important mediators playing a role in pain
modulation. The compounds slightly enhanced the
analgesic effect of ketoprofen in the writhing test
when given in combination. 
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